Introduction: Surgery is the standard treatment for pancreatic neuroendocrine tumors (pNETs), obtaining favorable results but associating high morbidity and mortality rates. This study assesses stereotactic body radiation therapy (SBRT) as a radical approach for small (< 2 cm) nonfunctioning pNETs.
Materials And Methods: From January 2017 to June 2023, 20 patients with small pNETs underwent SBRT in an IRB-approved study. Endpoints included local control, tolerance, progression-free survival, and overall survival (OS). Diagnostic assessments comprised endoscopy, CT scans, OctreScan or PET-Dotatoc, abdominal MRI, and histological confirmatory samples.
Results: In a 30-month follow-up of 20 patients (median age 55.5 years), SBRT was well-tolerated with no grade > 2 toxicity. 40% showed morphological response, 55% remained stable. Metabolically, 50% achieved significant improvement. With a median OS of 41.5 months, all patients were alive without local or distant progression or need for surgical resection.
Conclusion: SBRT is a feasible and well-tolerated approach for small neuroendocrine pancreatic tumors, demonstrating effective local control. Further investigations are vital for validation and extension of these findings.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s12094-024-03538-w | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Radiomics and dosiomics approaches to estimate lung function after stereotactic body radiation therapy in patients with lung tumors.
Radiol Phys Technol
January 2025
Department of Radiation Oncology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, 980-8574, Japan.
Lung function assessment is essential for determining the optimal treatment strategy for radiation therapy in patients with lung tumors. This study aimed to develop radiomics and dosiomics approaches to estimate pulmonary function test (PFT) results in post-stereotactic body radiation therapy (SBRT). Sixty-four patients with lung tumors who underwent SBRT were included.
View Article and Find Full Text PDFPerihilar and Intrahepatic Cholangiocarcinoma after Resection: Clinicopathological Characteristics, Outcomes, and Implications for Addition of Chemoradiotherapy.
Euroasian J Hepatogastroenterol
December 2024
Department of Radiation Oncology, Institute of Liver and Biliary Sciences, New Delhi, India.
Background: The purpose of the present study was to evaluate clinicopathological characteristics, patterns of recurrence, survival outcomes, and implications for the addition of chemoradiotherapy for patients with resected perihilar and intrahepatic cholangiocarcinoma (CCA).
Materials And Methods: For the present retrospective study, we identified 38 and 10 patients with resected perihilar and intrahepatic CCA. In perihilar CCA, adjuvant treatment was given as chemotherapy ( = 13) or chemoradiotherapy ( = 10).
Advanced Radiotherapy Technologies in Spine Tumors: What the Surgeon Needs to Know.
Global Spine J
January 2025
Department of Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Study Design: Narrative review of existing literature.
Objectives: Significant technological advancements in radiotherapy planning and delivery have enabled new radiotherapy techniques for the management of spine tumors. The objective of this study was to provide a comprehensive summary of these treatment techniques for practicing spine surgeons.
Editorial: Precision Medicine in Spinal Oncology.
Global Spine J
January 2025
Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
This special focus issue from the 2023-2024 AOSpine Knowledge Forum Tumor represents a culmination of years of experience devoted to advancing the care of patients with both metastatic and primary spinal tumors. We have learned much since the fundamental assessments of instability that led to the Spinal Instability Neoplastic Score (SINS), the grading of epidural disease utilizing the Epidural Spinal Cord Compression Scale (aka Bilsky grade), as well as the development of tumor-specific health related quality of life assessments such as the Spine Oncology Study Group Outcome Questionnaire (SOSGOQ). These tools have enabled us to make several prior recommendations for the appropriate use of advanced surgical techniques such as en bloc resection and the use of stereotactic body radiotherapy (SBRT) to optimize patient care.
View Article and Find Full Text PDFA Personalized Approach for Oligometastatic Prostate Cancer: Current Understanding and Future Directions.
Cancers (Basel)
January 2025
Department of Hematology-Oncology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Oligometastatic prostate cancer (OMPC) represents an intermediate state in the progression from localized disease to widespread metastasis when the radiographically significant sites are limited in number and location. With no clear consensus on a definition, its diagnostic significance and associated optimal therapeutic approach remain controversial, posing a significant challenge for clinicians. The current standard of care for metastatic disease is to start systemic therapy; however, active surveillance and targeted radiotherapy have become attractive options to mitigate the long-term effects of androgen deprivation therapy (ADT).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!